SCHEMBL246647

SCHEMBL246647

CCCN1CCCN=C1C

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C19 P33261 1/20 0.38
ALDH1A1 P00352 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TSHR P16473 3/20 0.36
HTT P42858 1/20 0.36
KDM4E B2RXH2 3/20 0.34
CYP1A2 P05177 1/20 0.33
PDE4A P27815 2/20 0.33
PDE4B Q07343 2/20 0.33
PDE4C Q08493 2/20 0.33
PDE4D Q08499 2/20 0.33
LMNA P02545 3/20 0.33
POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22068835 0.89 KDM4E (0.36) CYP2D6CYP3A4CYP2C19ALDH1A1TSHR
SCHEMBL17424836 0.88 TSHR (0.43) CYP2D6CYP3A4CYP2C19ALDH1A1MEN1
SCHEMBL14255598 0.87
SCHEMBL11121197 0.85 ALDH1A1 (0.43) CYP2D6ALDH1A1MEN1KMT2ATSHR
SCHEMBL19803145 0.83 TSHR (0.33) CYP2D6CYP3A4CYP2C19TSHRHTT
SCHEMBL242327 0.83
SCHEMBL18986133 0.82 KDM4E (0.33) ALDH1A1KDM4E
SCHEMBL17187362 0.82 KDM4E (0.36) CYP3A4CYP2C19ALDH1A1MEN1KMT2A
SCHEMBL22769465 0.79 KDM4E (0.32) ALDH1A1TSHRHTTKDM4E
SCHEMBL11135987 0.79 KDM4E (0.32) ALDH1A1TSHRHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 163 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11225450-B2 Processes for preparing calixarenes SI GROUP, INC. (US) 2022-01-18 US claimed
US-20210047253-A1 PROCESSES FOR PREPARING CALIXARENES SI GROUP, INC. 2021-02-18 US claimed
US-10781154-B2 Processes for preparing calixarenes SI GROUP, INC. (US) 2020-09-22 US claimed
US-10640641-B2 Curable coating compositions of silane functional polymers KING INDUSTRIES (US) 2020-05-05 US claimed
US-20200062953-A1 CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS KING INDUSTRIES 2020-02-27 US claimed
US-20190248721-A1 PROCESSES FOR PREPARING CALIXARENES SI GROUP, INC. 2019-08-15 US claimed
US-10336863-B2 Curable composition having a special catalyst/softner system HENKEL AG & CO. KGAA (DE) 2019-07-02 US claimed
US-20180237635-A1 CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS KING INDUSTRIES 2018-08-23 US claimed
US-9976028-B2 Curable coating compositions of silane functional polymers KING INDUSTRIES (US) 2018-05-22 US claimed
WO-2016137881-A1 CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS KING INDUSTRIES (US) 2016-09-01 WO claimed
US-20160244606-A1 CURABLE COATING COMPOSITIONS OF SILANE FUNCTIONAL POLYMERS KING INDUSTRIES 2016-08-25 US claimed
US-8013080-B2 Curable composition KANEKA CORPORATION (JP) 2011-09-06 US claimed
EP-4692247-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2026-02-11 EP disclosed
US-20260022211-A1 CURABLE COMPOSITION KANEKA CORPORATION (JP) 2026-01-22 US disclosed
EP-4656672-A1 METHOD FOR PRODUCING CURABLE COMPOSITION Kaneka Corporation (JP) 2025-12-03 EP disclosed
EP-4569023-A1 COMBINATION OF CATALYTIC COMPONENTS PolyU GmbH (DE) 2025-06-18 EP disclosed
EP-1990370-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-11-12 EP disclosed
EP-1985666-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-10-29 EP disclosed
EP-1939256-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-07-02 EP disclosed
EP-1930376-A1 CURABLE COMPOSITION Kaneka Corporation (JP) 2008-06-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210047253-A1 PROCESSES FOR PREPARING CALIXARENES CALU, CALD1, CALR CYP2D6 1274/4885CYP3A4 262/4885CYP2C19 756/4885
US-20190248721-A1 PROCESSES FOR PREPARING CALIXARENES CALU, CALD1, CALR CYP2D6 1274/4885CYP3A4 262/4885CYP2C19 756/4885
US-11225450-B2 Processes for preparing calixarenes CALU, CALD1, CALR CYP2D6 1274/4885CYP3A4 262/4885CYP2C19 756/4885
US-20260022211-A1 CURABLE COMPOSITION H1-4, H1-0, H1-2 CYP2D6 3557/4885CYP3A4 2959/4885CYP2C19 3948/4885
US-10781154-B2 Processes for preparing calixarenes CALU, CALD1, CALR CYP2D6 1274/4885CYP3A4 262/4885CYP2C19 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.